More than 60% of children with systemic lupus erythematosus (SLE) develop lupus nephritis (LN). Neutrophil gelatinase-associated lipocalin (NGAL) is a protein secreted by leukocytes during inflammation and is overexpressed in the kidneys following ischemic and nephrotoxic damage.
Aim
To study urinary and serum NGAL in children with SLE and investigate their possible role as markers of renal involvement.
Methods
Urinary and serum levels of NGAL were assessed in 33 children with active SLE (22 with and 11 without LN) and compared to 15 matched controls.
Results
Children with SLE had elevated urinary NGAL as compared to controls (P < 0.001). Levels of urinary NGAL were higher in patients with LN than those without LN (P < 0.001). In patients with LN, serum levels of NGAL were not significantly different from controls (P = 0.4) and urinary NGAL correlated with the renal score of the Systemic Lupus Erythematosus Disease Activity Index (r = 0.5, P = 0.02) but not with serum NGAL (P = 0.5). Urinary NGAL was significantly predictive of class III and IV LN (P = 0.005) with 91% sensitivity and 70% specificity to levels ≥10.07 ng/mg creatinine.
Conclusions
Urinary NGAL is a sensitive marker of proliferative nephritis in juvenile SLE.
KorbetSMLewisEJSchwartzMMReichlinMEvansJRohdeRD. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis2000; 35: 904–914.
2.
PerfumoFMartiniA. Lupus nephritis in children. Lupus2005; 14: 83–88.
3.
GloorJM. Lupus nephritis in children. Lupus1998; 7: 639–643.
4.
XuSYPauksenKVengeP. Serum measurements of human neutrophil lipocalin (HNL) discriminate between acute bacterial and viral infections. Scand J Clin Lab Invest1995; 55: 125–131.
5.
NielsenBSBorregaardNBundgaardJRTimshelSSehestedMKjeldsenL. Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut1996; 38: 414–420.
6.
MishraJMaQPradaA. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol2003; 14: 2534–2543.
7.
MishraJMoriKMaQKellyCBaraschJDevarajanP. Neutrophil gelatinase-associated lipocalin: A novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol2004; 24: 307–315.
8.
TrachtmanHChristenECnaanA. Urinary neutrophil gelatinase-associated lipocalcin in D+HUS: A novel marker of renal injury. Pediatr Nephrol2006; 21: 989–994.
9.
SupavekinSZhangWKucherlapatiRKaskelFJMooreLCDevarajanP. Differential gene expression following early renal ischemia/reperfusion. Kidney Int2003; 63: 1714–1724.
10.
DevarajanPMishraJSupavekinSPattersonLTSteven PotterS. Gene expression in early ischemic renal injury: Clues towards pathogenesis, biomarker discovery, and novel therapeutics. Mol Genet Metab2003; 80: 365–376.
11.
DevarajanP. Cellular and molecular derangements in acute tubular necrosis. Curr Opin Pediatr2005; 17: 193–199.
12.
NguyenMTRossGFDentCLDevarajanP. Early prediction of acute renal injury using urinary proteomics. Am J Nephrol2005; 25: 318–326.
13.
MishraJMaQKellyC. Kidney NGAL is a novel early marker of acute injury following transplantation. Pediatr Nephrol2006; 21: 856–863.
14.
TanEMCohenASFriesJF. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982; 25: 1271–1277.
WeeningJJD'AgatiVDSchwartzMM. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol2004; 15: 241–250.
17.
IlleiGGTackeyELaptevaLLipskyPE. Biomarkers in systemic lupus erythematosus: II. Markers of disease activity. Arthritis Rheum2004; 50: 2048–2065.
18.
IlleiGGTackeyELaptevaLLipskyPE. Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability. Arthritis Rheum2004; 50: 1709–1720.
19.
MerrillJTBuyonJP. The role of biomarkers in the assessment of lupus. Best Pract Res Clin Rheumatol2005; 19: 709–726.
20.
HahnBH. Antibodies to DNA. N Engl J Med1998; 338: 1359–1368.
BrunnerHIMuellerMRutherfordC. Urinary neutrophil gelatinase-associated lipocalin as a biomarker of nephritis in childhood-onset systemic lupus erythematosus. Arthritis Rheum2006; 54: 2577–2584.
25.
SuzukiMWiersKMKlein-GitelmanMS. Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis. Pediatr Nephrol2008; 23: 403–412.
26.
MishraJDentCTarabishiR. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet2005; 365: 1231–1238.
27.
HinzeCHSuzukiMKlein-GitelmanM. Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity. Arthritis Rheum2009; 60: 2772–2781.
28.
RubinsteinTPitashnyMLevineB. Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis. Rheumatology (Oxford)2010; 49: 960–971.
29.
KianiANWuTFangH. Urinary vascular cell adhesion molecule, but not neutrophil gelatinase-associated lipocalin, is associated with lupus nephritis. J Rheumatol2012; 39: 1231–1237.
30.
PitashnyMSchwartzNQingX. Urinary lipocalin-2 is associated with renal disease activity in human lupus nephritis. Arthritis Rheum2007; 56: 1894–1903.
31.
CrossJJayneD. Diagnosis and treatment of kidney disease. Best Pract Res Clin Rheumatol2005; 19: 785–798.
32.
CorwinHLSchwartzMMLewisEJ. The importance of sample size in the interpretation of the renal biopsy. Am J Nephrol1988; 8: 85–89.
33.
AdamsAMacDermottEJLehmanTJ. Pharmacotherapy of lupus nephritis in children: A recommended treatment approach. Drugs2006; 66: 1191–1207.
34.
KaSMRifaiAChenJH. Glomerular crescent-related biomarkers in a murine model of chronic graft versus host disease. Nephrol Dial Transplant2006; 21: 288–298.
35.
BrunnerHIBennettMRMinaR. Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis. Arthritis Rheum2012; 64: 2687–2697.
